Weigao Group (01066) has released its interim results for the six months ended June 30, 2026. The group recorded revenue of RMB 6.849 billion, representing a year-on-year increase of 3.08%. Net profit attributable to owners of the company stood at RMB 774 million, a decrease of 23.23% compared to the same period last year. Earnings per share reached RMB 0.17, with an interim dividend of RMB 0.0854 per share proposed.

During the period, revenue from medical device products amounted to approximately RMB 3.364 billion, up 5.4% year-on-year. Despite the increase in revenue, operating profit experienced a year-on-year decline of nearly 10%, primarily due to price reductions on several core products resulting from centralized procurement policies implemented since the third quarter of 2025. Nevertheless, the company achieved a significant sequential improvement in operating profit by adjusting its product mix and substantially optimizing marketing expenses. The operating profit margin remained stable at above 10%.